GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Fit individuals often have full heads of hair, possibly due to lifestyle factors like exercise and diet, while those who are less fit tend to experience more hair loss. Some fit individuals may also use treatments like finasteride and minoxidil to maintain their hair.
The user is considering getting blood work to investigate the cause of ongoing hair loss despite using finasteride and dutasteride. Others suggest that while blood tests can provide useful health information, they may not change the hair treatment outcome.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.